RGRandolph L. Geary

Randolph L. Geary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Randolph L. Geary has a total of 317 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design and Implementation of a Digital Health Platform for Measuring Peripheral Artery Disease Outcomes: The Project VOICE Pilot Study

    by Matthew A. Corriere, Donna Keith, Timothy E. Craven, Justin Brothwell Hurie, Randolph L. Geary, Gabriela Velazquez-Ramirez, Matthew S. Edwards

  • Open Access

    Morbidity and Mortality After Acute Lower Extremity Embolization: A Ten-Year Experience

    by Kelly Kempe, Brett Starr, Arsalla Islam, Jeanette Stafford, Ashley Mooney, Emily Lagergren, Matthew A. Corriere, Randolph L. Geary, Matthew S. Edwards

  • Contralateral renal disease in patients undergoing renal artery aneurysm repair: the fate of the "other" kidney and implications for clinical management

    by Sarah M. Carter, Michael R. Buckley, Jeanette S. Andrews, Matthew S. Edwards, Justin B. Hurie, Randolph L. Geary, Christopher J. Godshall, George Plonk, Matthew A. Corriere

  • Outcomes of Acute Surgical Conversion during Endovascular Aortic Aneurysm Repair

    by William B. Newton, Jeanette S. Andrews, Matthew A. Corriere, Philip P. Goodney, Racheed J. Ghanami, Randolph L. Geary, Christopher J. Godshall, Kimberley J. Hansen, Matthew S. Edwards

  • Diastolic Function Predicts Survival After Renal Revascularization

    by Racheed J. Ghanami, Hamza Rana, Tim Craven, Matthew A. Corriere, Phillip Moore, John Hoyle, Randolph L. Geary, Matthew S. Edwards, Christopher J. Godshall, Kimberley J. Hansen

  • Contributors

    by Ahmed M. Abou-Zamzam, Christopher J. Abularrage, Ali F. AbuRahma, Stefan Acosta, Harold P. Adams, Gilbert Aidinian, A. Ruchan Akar, Yves S. Alimi, George Andros, Juan I. Arcelus, et al.

  • Expression Profiling Identifies 147 Genes Contributing to a Unique Primate Neointimal Smooth Muscle Cell Phenotype

    by Randolph L. Geary, James M. Wong, Anthony Rossini, Stephen M. Schwartz, Lawrence D. Adams

    Objective— This study represents the first in an effort to systematically characterize different intimas by using expression array analysis. Methods and Results— We compared smooth muscle cells (SMCs) of the neointima formed 4 weeks after aortic grafting with those from normal aorta and vena cava from cynomolgus monkeys. Hybridization to cDNA arrays identified subsets of 147 and 45 genes differentially expressed in the neointima versus the aorta and vena cava, respectively. The expression pattern differentiating neointima from aortic SMCs was characterized largely by suppression. Only 13 genes were induced in the neointima: 7 encoded matrix proteins (6 collagens and 1 versican) and 2 encoded inducers of matrix synthesis (osteoblast-specific factor-2/Cbfa1 and connective tissue growth factor). The genes suppressed most in the neointima included the regulator of G-protein signaling-5, SPARClike-1/hevin, and nonmuscle myosin heavy chain-B. A smaller gene set differentiated the neointima from the vena cava. Most were induced (39 of 45 genes), and overlap with the neointima-aorta set was significant (10 of 13 genes). Array results were validated with Northern analysis, in situ hybridization, or immunohistochemistry. Conclusions— These data underscore the importance of matrix synthesis in neointimal maturation, and novel genes, newly associated with neointimal SMCs (regulator of G-protein signaling-5 and osteoblast-specific factor-2/Cbfa1), have raised new hypotheses regarding the pathogenesis of intimal hyperplasia.


  • Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates

    by Gregory S. Cherr, Stephen J. Motew, Jeffrey A. Travis, Juergen Fingerle, Larry Fisher, Mike Brandl, J. Koudy Williams, Randolph L. Geary

    Determinants of restenosis after angioplasty include constrictive remodeling and intimal hyperplasia. Both processes require extensive matrix turnover, so matrix metalloproteinases (MMPs) have become potential targets of antirestenosis therapies. We studied the effects of RO113-2908, a broad-spectrum MMP inhibitor (MMPI), on the response to iliac artery angioplasty and stenting in atherosclerotic cynomolgus monkeys. Lumen diameter (LD) was measured angiographically, and artery wall geometry was assessed after perfusion-fixation at 4 weeks. Angiogenesis was measured in subcutaneous polyvinyl alcohol disks. Treatment provided significant, systemic MMP inhibitory activity (97±2.2% inhibition of 25 nmol/L MMP-12 by serum) and inhibited angiogenesis ( P =0.007). In contrast, loss of gain in LD ( P =0.73) and constrictive remodeling (external elastic lamina area ratio [injured/uninjured×100]: MMPI, 106.3±9.6% vs control, 119.9±7.2%; P =0.27) were not substantially improved 4 weeks after angioplasty. Treatment also failed to reduce intimal hyperplasia after angioplasty (intimal area [mm 2 ]: 1.4±0.3 vs 1.6±0.2, P =0.65) or stenting (2.4±0.2 vs 2.8±0.2, P =0.12). In summary, inhibition of MMP activity reduced angiogenesis but failed to prevent constrictive remodeling or intimal hyperplasia after angioplasty and stenting in atherosclerotic primates. Additional research is needed to define the spectrum of matrix-degrading proteases critical in healing atherosclerotic arteries after angioplasty.


    • 1 January 2002
      • Vol. 35  (1) , 94-9

    Survival of young patients after abdominal aortic aneurysm repair.

    by Gregory S Cherr, Matthew S Edwards, Timothy E Craven, Pavel J Levy, John Ligush, Randolph L Geary, George W Plonk, Kimberley J Hansen

    This study assessed the cardiovascular disease, perioperative results, and survival after surgical abdominal aortic aneurysm repair in young patients (< or = 50 years) compared with randomly selected older patients who also underwent abdominal aortic aneurysm repair. We reviewed hospital records to identify young and randomly selected control patients (3 for each young patient, > or = 65 years, matched for year of operation) with degenerative (atherosclerotic) abdominal aortic aneurysms undergoing repair between Jan 1, 1988, and Mar 31, 2000. Patients with congenital aneurysms, pseudoaneurysms, aortic dissections, post-coarctation dilations, aortic infection, arteritis, or aneurysms isolated to the thoracic aorta were excluded. Mortality data and cause of death were obtained from medical records and the National Death Index Among 1168 patients who underwent abdominal aortic aneurysm repairs, 19 young patients (1.6%) and 57 control patients were identified. The mean age was 48.4 years in the young group and 72.2 years in the control group. There were no differences in sex or race between the two groups. When comparing existing cardiovascular disease between the groups, there were no differences in the incidence of earlier coronary revascularization (26% vs 16%) or non-cardiac vascular surgery (5% vs 9%), but aneurysms were more commonly symptomatic in young patients (53% vs 21%; P <.01). Aneurysmal disease was limited to the infrarenal aorta in similar proportions of patients (89% vs 88%). No statistically significant differences were seen in the incidence of perioperative deaths (16% young vs 9% control; P =.40) or postoperative complications (37% young vs 26% control; P =.38). The estimated survival rate of the young group was not different from that of the control group (3-year survival rate, 73% vs 69%; P =.32) or the entire cohort of patients (older than 50 years; n = 1101) who underwent repair of abdominal aortic aneurysms during the study period (3-year survival 73% vs 75%; P =.63) After abdominal aortic aneurysm repair, young patients had perioperative results and follow-up mortality rates similar to those of control patients. Cardiovascular disease was the predominant cause of death after abdominal aortic aneurysm repair in the young patients. When compared with an age older than 50 years at the time of abdominal aortic aneurysm repair, young age alone was not associated with increased survival.


  • Angiotensin-Converting Enzyme Expression in Human Carotid Artery Atherosclerosis

    by Masayo Fukuhara, Randolph L. Geary, Debra I. Diz, Patricia E. Gallagher, John A. Wilson, Steven S. Glazier, Richard H Dean, Carlos M. Ferrario

    —Angiotensin-converting enzyme (ACE) inhibitors reduce the progression of atherosclerosis in animal models and reinfarction rates after myocardial infarction in humans. Although expression of components of the renin-angiotensin system has been reported in human coronary arteries, no data regarding their presence in carotid arteries, a frequent site for the occurrence of atherosclerosis plaques, are available. The following study sought to determine whether ACE mRNA and protein can be detected in human carotid atheromatous lesions. Twenty-four intact endarterectomy specimens were obtained from patients with severe carotid occlusive disease (17 males and 7 females, aged 68±1 years) and fixed within 30 minutes. Carotid artery specimens contained advanced Stary type V and VI lesions, and human ACE mRNA expression and protein were localized in cross sections by the combination of in situ hybridization and immunohistochemistry. Cell type–specific antibodies were used to colocalize ACE to smooth muscle cells, endothelial cells, macrophages, or lymphocytes. ACE protein was localized in the intima, whereas the overlying media was largely free of ACE staining. In less complicated lesions, ACE staining was modest and could be visualized in scattered clusters of macrophages and on the luminal side of carotid artery vascular endothelium. Smooth muscle cells were largely negative. ACE staining increased as lesions became more complex and was most prominent in macrophage-rich regions. The shoulder regions of plaques contained numerous ACE-positive macrophage foam cells and lymphocytes. In these areas, microvessels were positive for endothelial cell and smooth muscle cell ACE expression. However, microvessels in plaques free of inflammatory cells were stained only faintly for ACE expression. Labeling for ACE mRNA mirrored the pattern of protein expression, localizing ACE mRNA to macrophages and microvessels within the intima. In conclusion, atherosclerosis alters carotid artery ACE production, increasing transcription and translation within regions of plaque inflammation. These data provide another important mechanism by which inflammation associated with increased ACE expression may contribute to the progression of atherosclerosis.